

# TAKE A STAND FOR LONGER SURVIVAL



## Median Overall Survival<sup>2</sup>

**9.3 Months** with Xospata **VS** **5.6 Months** with salvage chemotherapy

HR=0.64 (95% CI: 0.49, 0.83); P< 0.001



## Percentage of patients underwent transplantation<sup>2</sup>

**25.5%** with Xospata (n=63/247) **VS** **15.3%** with salvage chemotherapy (n= 19/124)

Recommended by:<sup>3-5</sup>



GOOD SCIENCE  
BETTER MEDICINE  
BEST PRACTICE

**NICE** National Institute for  
Health and Care Excellence

### Abbreviations:

CI: confidence interval; FLT3: FMS-like tyrosine kinase 3; HR: hazard ratio; OS: overall survival

### References:

1. Xospata® Prescribing Information Hong Kong 2. Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. *N Engl J Med* 2019;381(18):1728-40 3. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Acute myeloid leukemia (Version 2. 2021 -November) 4. Heuser M, et al. *Annals of Oncology*. 2020;31(6): 697-712. 5. NICE technology appraisal guidance. Available at: <https://www.nice.org.uk/guidance/ta642/resources/gilteritinib-for-treating-relapsed-or-refractory-acute-myeloid-leukaemia-pdf-82609134829765>, accessed on 22 Mar 2022.

Please find the abbreviated  
prescribing information here:



Email us at [pv@hk.astellas.com](mailto:pv@hk.astellas.com) when there is any Adverse Event

**Astellas Pharma Hong Kong Company Limited**  
Unit 1103-08, 11/F, Tower 1, Grand Century Place, 193 Prince Edward Rd. West, Mongkok, Kowloon, Hong Kong  
Tel: (852) 2377 9801 | Fax: (852) 2856 1440 | Email: [info@hk.astellas.com](mailto:info@hk.astellas.com)

MAT-HK-XOS-2026-00001 | Jan 2026